<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31464894</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-5964</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>98</Volume>
            <Issue>35</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Medicine</Title>
          <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The role of 18F-FDG PET/CT in management of paraneoplastic limbic encephalitis combined with small cell lung cancer: A case report.</ArticleTitle>
        <Pagination>
          <StartPage>e16593</StartPage>
          <MedlinePgn>e16593</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e16593</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000016593</ELocationID>
        <Abstract>
          <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Limbic encephalitis is one of the most common paraneoplastic neurological disorders (PND). The role of brain Fluorine-18-fluorodeoxyglucose position emission tomography/computed tomography (CT) in paraneoplastic limbic encephalitis (PLE) and of the whole body 18F-FDG PET/CT in this setting, remains still not well defined.</AbstractText>
          <AbstractText Label="PATIENT CONCERNS" NlmCategory="METHODS">We report a case of a patient with chronic inflammatory rheumatism, psoriasis and Hashimoto thyroiditis and subsequent appearance of static and dynamic ataxia and episodic memory deficit who was diagnosed as PLE combined with small cell lung cancer (SCLC).</AbstractText>
          <AbstractText Label="DIAGNOSES" NlmCategory="METHODS">The diagnosis of SCLC was made with EBUS-TBNA of a mediastinal lymph node.</AbstractText>
          <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Whole-body 18F-FDG PET/CT was performed for the initial staging of SCLC, in the planning of radiotherapy treatment, to evaluate therapeutic response and in the follow-up. A dedicated brain scan was included to the same PET session. Whole-body contrast enhanced computed tomography (CT) and contrast enhanced whole-brain MRI were also performed.</AbstractText>
          <AbstractText Label="OUTCOMES" NlmCategory="RESULTS">She was administered neoadjuvant chemioterapy with Cisplatin and Etoposide with concomitant radiotherapy treatment. Whole body 18F-FDG PET/CT showed a complete metabolic response already after 3 cycles of chemioterapy. Brain functional study showed a metabolic pattern characterized by the migration of hypermetabolism in the bilateral hippocampal areas during the therapeutic treatment, which correlated with the persistence of clinical symptoms.</AbstractText>
          <AbstractText Label="LESSONS" NlmCategory="CONCLUSIONS">In the era of personalized medicine and targeted therapy, this case highlights the importance of the 18F-FDG PET/CT study as an accurate tool to identify PLE and to guide the diagnostic work-up of the underlying tumor. Considering that most of these are 18F-FDG avid tumors and that the 18F-FDG PET/CT scan is often added to the diagnostic work-up when screening patients for malignancy, this functional imaging can play a decisive role.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Castagnoli</LastName>
            <ForeName>Helga</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Service Department Macerata Hospital, ASUR Marche AV3, Nuclear Medicine Unit.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manni</LastName>
            <ForeName>Carlo</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Service Department Macerata Hospital, ASUR Marche AV3, Nuclear Medicine Unit.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marchesani</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Pulmonary Unit ASUR Marche AV3.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rossi</LastName>
            <ForeName>Gloria</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Service Department Macerata Hospital, ASUR Marche AV3, Medical Physics Unit, Macerata, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fattori</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Service Department Macerata Hospital, ASUR Marche AV3, Medical Physics Unit, Macerata, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Capoccetti</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Service Department Macerata Hospital, ASUR Marche AV3, Nuclear Medicine Unit.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Medicine (Baltimore)</MedlineTA>
        <NlmUniqueID>2985248R</NlmUniqueID>
        <ISSNLinking>0025-7974</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0Z5B2CJX4D</RegistryNumber>
          <NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6PLQ3CP4P3</RegistryNumber>
          <NameOfSubstance UI="D005047">Etoposide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005047" MajorTopicYN="N">Etoposide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020363" MajorTopicYN="N">Limbic Encephalitis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055752" MajorTopicYN="N">Small Cell Lung Carcinoma</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051598" MajorTopicYN="N">Whole Body Imaging</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have no conflicts of interests to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31464894</ArticleId>
        <ArticleId IdType="pmc">PMC6736484</ArticleId>
        <ArticleId IdType="doi">10.1097/MD.0000000000016593</ArticleId>
        <ArticleId IdType="pii">00005792-201908300-00006</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Darnell RB, Posner JB.
Paraneoplastic syndromes affecting the nervous system. Semin Oncol
2006;33:270–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16769417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ances BM, Vitaliani R, Taylor RA, et al. 
Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain
2005;128:1764–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1939694</ArticleId>
            <ArticleId IdType="pubmed">15888538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, et al. 
Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain
2000;123:1481–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC, et al. 
Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry
2004;75:1135–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kassubek J, Juengling FD, Nitzsche EU, et al. 
Limbic encephalitis investigated by 18FDG-PET and 3D MRI. J Neuroimaging
2001;11:55–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11198529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheid R, Lincke T, Voltz R, et al. 
Serial 18F-fluoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis. Arch Neurol
2004;61:1785–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15534190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Bataller L.
Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders. Hematol Oncol Clin North Am
2006;20:1319–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1920176</ArticleId>
            <ArticleId IdType="pubmed">17113466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heine J, Prüss H, Bartsch T, et al. 
Imaging of autoimmune encephalitis - relevance for clinical practice and hippocampal function. Neuroscience
2015;309:68–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26012492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Younes-Mhenni S, Janier MF, Cinotti L, et al. 
FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain
2004;127:2331–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15361417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Titulaer MJ, Balu R, et al. 
A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol
2016;15:391–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5066574</ArticleId>
            <ArticleId IdType="pubmed">26906964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panzer J, Dalmau J.
Movement disorders in paraneoplastic and autoimmune disease. Send to Curr Opin Neurol
2011;24:346–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3705177</ArticleId>
            <ArticleId IdType="pubmed">21577108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincent A, Buckley C, Schott JM, et al. 
Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain
2004;127:701–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14960497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Tuzun E, Wu HY, et al. 
Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol
2007;61:25–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2430743</ArticleId>
            <ArticleId IdType="pubmed">17262855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Graus F, Villarejo A, et al. 
Clinical analysis of anti-Ma2-associated encephalitis. Brain
2004;127:1831–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15215214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thieben MJ, Lennon VA, Boeve BF, et al. 
Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology
2004;62:1177–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15079019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Keime-Guibert F, Rene R, et al. 
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain
2001;124:1138–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11353730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuzun E, Dalmau J.
Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist
2007;13:261–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17848866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alamowitch S, Graus F, Uchuya M, et al. 
Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain
1997;120:923–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9217677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gould MK, Maclean CC, Kuschner WG, et al. 
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA
2001;285:914–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11180735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu D, Wang Y, Wang L, et al. 
Prognostic value of the maximum standardized uptake value of pre-treatment primary lesions in small-cell lung cancer on 18F-FDG PET/CT: a meta-analysis. Acta Radiol
2018;59:1082–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29256260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>NCCN Clinical Practice Guidelines in Oncology. Small cell lung cancer. Version 2.2018-January 17, 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Haugen BR, Alexander EK, Bible KC, et al. 
2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid
2016;26:1–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4739132</ArticleId>
            <ArticleId IdType="pubmed">26462967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soelberg KK, Bonnema SJ, Brix TH, et al. 
Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid
2012;22:918–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22827552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azad A, Chionh F, Scott AM, et al. 
High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol
2010;12:443–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19921339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl RL, Jacene H, Kasamon Y, et al. 
From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med
2009;50:122S–50S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2755245</ArticleId>
            <ArticleId IdType="pubmed">19403881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto Y, Kameyama R, Murota M, et al. 
Early assessment of therapeutic response using FDG PET in small cell lung cancer. Mol Imaging Biol
2009;11:467–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19434460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mac Manus MP, Hicks RJ, Matthews JP, et al. 
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non_small-cell lung cancer. J Clin Oncol
2003;21:1285–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12663716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer BM, Mortensen J, Langer SW, et al. 
PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer
2006;54:41–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16919841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ziai D, Wagner T, El Badaoui A, et al. 
Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging
2013;13:73–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3589951</ArticleId>
            <ArticleId IdType="pubmed">23466871</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
